JHJacek Hermann

Jacek Hermann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jacek Hermann has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Comparison between application of platelet rich plasma and mucosal advancement flap in patients with high transsphincteric anal fistulas: a randomized control trial

    by Jacek Hermann, Jarosław Cwaliński, Tomasz Banasiewicz, Barbara Kołodziejczak

    Background: There is still a search for a standard method of therapy for high anal fistulas. The aim of this trial was a comparison between a modified two stage minimally invasive procedure, consisting of loose‐seton placement with the subsequent application of platelet rich plasma with mucosal advancement flap for the treatment of high transsphincteric anal fistulas of crypto‐glandular origin.Methods: The study was designed as a prospective, randomized trial including 96 patients. Curettage of fistulous tracts, and loose‐seton placement was performed in those patients with active inflammation, and if the diameter of a fistulous tract exceeded 3 mm. Afterwards, the patients were randomly assigned to either the PRP group or MAF group, consisting of 49 patients, and 47 patients, respectively.Results: There was no significant statistical difference (p = 0.152) between both investigated groups of patients regarding closure of fistulas since it was achieved in 35 (71.43%) patients from group I, compared to 27 (57.45%) patients from group II. The diameter of fistulous tracts below 4 mm exerted a significant impact (p < 0.001) on the healing process after PRP application because fistulas with the narrow tracts were closed in 34 (87.18%) patients, whereas a wider fistula was healed in 1 (10%) patient.Conclusion: The local application of PRP in high, unbranched, and with narrow tracts trans‐sphincteric anal fistulas of crypto‐glandular origin, following loose‐seton drainage is an effective, simple, and a safe method of therapy with a low rate of morbidity.


  • Open Access

    Application of platelet-rich plasma in rectovaginal fistulas in the patients with ulcerative colitis

    by Jacek Hermann, Jarosław Cwaliński, Tomasz Banasiewicz

    Background: There is a need for other than surgical methods of therapy for small and low rectovaginal fistulas (RVF) in the course of inflammatory bowel diseases (IBD), such as application of fibrin sealants, stem cells, biological therapy, or platelet-rich plasma. The aim of this study was to evaluate the results of the treatment after local application of PRP in aforementioned fistulas, exclusively in the patients with ulcerative colitis (UC). Patients and methods: Medical records of 13 patients with small and low-lying, active RVF in the course of UC, and after restorative proctocolectomy for UC were evaluated. Curettage of fistulous tracts was performed with the following application of PRP in all patients. Results: Complete closure of RVF was achieved after the first injection in 4 patients, 3 women healed their fistulas following the second application, and two of them closed RVF after 3 injections. To sum up, the complete closure of RVF was achieved in 9 (69%) patients. Fistulas remained closed from 6 to 12 months. Conclusions: The application of PRP in small, low, and recurrent IBD anal fistulas is effective, simple, and safe with an acceptable rate of healing. This therapy might also precede any further, surgical methods of treatment.


  • Open Access

    ASSESSMENT OF RECURRENT ANAL FISTULAS TREATMENT WITH PLATELET-RICH PLASMA

    by Jarosław CWALIŃSKI, Jacek Hermann, Jacek Paszkowski, Tomasz Banasiewicz

    BACKGROUND: Surgical treatment of recurrent anal fistulas can lead to numerous complications, including fecal incontinence. Therefore, sphincter preserving techniques are gaining more popularity. OBJECTIVE: The aim of the study was to assess effectiveness of platelet-rich plasma (PRP) therapy in the patients with recurrent cryptoglandular anal fistulas. METHODS: A cohort of 18 patients with anal fistulas was enrolled into a preliminary and prospective trial. They were divided into two groups consisting of eight and ten patients respectively. PRP was injected locally in all patients, however in the group II it was applied after 7 days drainage of fistulas with polyurethane foam or negative pressure wound therapy. On average, three doses of PRP were administered, but with the opportunity to double the number of applications if it was clinically justified. The patients were evaluated in an out-patient department after fortnight and then in 1, 6, and 12 months following the last PRP application. RESULTS: Anal fistulas were closed in 4 (50%) patients from the group I and in 7 (70%) patients form the group II. Although, the difference between both groups was not statistically significant, PRP therapy should be preceded with fistulous tract drainage in all patients. Summarizing, that successful result was achieved in 11 (60%) patients from the entire group of 18 participants. CONCLUSION: The rate of recurrent cryptoglandular anal fistulas closure reaching 60%, after topical treatment with PRP, exceeds the results of other sphincter-saving methods of treatment. Therefore, it might become a novel method of anal fistulas therapy.


  • Novel Sphincter-preserving Therapies for Recurrent Anal Fistulas

    by Jacek Hermann, Jarosław Cwaliński, Tomasz Banasiewicz, Barbara Kołodziejczak


  • Endoscopic vacuum assisted closure of gastrocutaneous fistula after sleeve gastrectomy combined with fibrin sealant

    by Jarosław CWALIŃSKI, Jacek Hermann, Jacek Paszkowski, Tomasz Banasiewicz

    Treatment of gastrointestinal fistulas after staple line leaks is difficult and non-invasive procedures such as endoclips, stents or endoscopic vacuum assisted closure (E-VAC) are sometimes not adequate. Fibrin sealants (FS) may promote healing, although today are used mainly to prevent anastomosis dehiscence within digestive tract. The authors present a 37-year-old female patient who developed a chronic gastrocutaneous fistula after sleeve gastrectomy for severe obesity treated successfully with a combination of E-VAC and a fibrin sealant. Long term peritoneal drainage, total parenteral nutrition, and antibiotic therapy for the next six weeks failed to close the leakage. Ultimately the fistula was closed after 6 changes of E-VAC and final implementation of a fibrin sealant. The duration of treatment was 81 days, including 34 days of E-VAC treatment and FS application. Complete closure of the fistula was visualized on gastroscopy six weeks after the treatment.


  • Open Access

    Endoscopic vacuum assisted closure of esophagogastric anastomosis dehiscence: A case report

    by Jarosław Cwaliński, Jacek Hermann, Mariusz Kasprzyk, Tomasz Banasiewicz

    Esophagogastric leakage is one of the most severe postoperative complications. Partial disruption of the anastomosis, can be successfully treated with an endoscopic vacuum assisted closure (E-VAC). The advantage of that method of treatment is the ability to adjust a vacuum dressing individually to the size of the dehiscence and thus to reduce the risk of a secondary fistula or abscess. The authors present two patients with postoperative gastroesophageal leakage treated successfully with E-VAC. Two male patients developed a potentially life threatening esophagogastric leakage. Patient A underwent resection of the distal half of the esophagus and upper part of the stomach due to Siewert type II adenocarcinoma of the gastroesophageal junction. Proximal resection of the stomach was performed in the patient B after massive bleeding from Mallory-Weiss tears. Both patients were treated successfully with an individually adapted E-VAC with concomitant correction of fluid and electrolyte disturbances, and treatment of sepsis with appropriate antibiotics. Endoscopic vacuum closure is an effective alternative to endoscopic stenting or relaparotomy. Through individual approach it allows a more accurate assessment of healing.


  • Open Access

    One-shot dalbavancin infusion combined with vacuum-assisted closure of Crohn’s anal fistulas

    by Jacek Hermann, Hanna Tomczak, Barbara Kołodziejczak, Dorota Mańskowska-Wierzbicka, Tomasz Banasiewicz, Ryszard Marciniak

    Cite this article as: Hermann J, Tomczak H, Kolodziejczak B, Mańskowska-Wierzbicka D, Banasiewicz T, Marciniak R. One-shot dalbavancin infusion combined with vacuum-assisted closure of Crohn’s anal fistulas. Turk J Gastroenterol 2019; 30: 113-4.

  • Open Access

    Treatment of Crohn's anal fistulas guided by magnetic resonance imaging

    by Jacek Hermann, Piotr Stajgis, Barbara Kołodziejczak, Piotr Eder, Tomasz Banasiewicz

    Introduction: Clinical evaluation of the Crohn's anal fistulas (CF) closure is inadequate to some extent due to earlier closure of cutaneous openings compared to fistulous tracts. There is a need for a more accurate method of assessment. Aim: To compare clinical signs of CF with radiological findings, before and after treatment, to follow complete closure. Material and methods: It was a retrospective study of 23 patients suffering from CF admitted to a single specialist centre, who were treated with a combination of surgical and biological therapy. Fistula healing was evaluated with fistula drainage assessment classification (FDA), perianal disease activity index (PDAI), and van Assche magnetic resonance imaging score (MRI) before and 3 months after surgery and induction of the biological treatment. Results: Clinical response occurred in 13 (57%) patients 3 months after induction treatment. Complete clinical response was achieved in 8 (35%) patients, whereas partial response occurred in 5 (22%) patients. Persistence of a fistula tract was visualised on MRI in 4 (50%) patients with clinical closure. Conclusions: The healing process of CF should be monitored by MRI due to the discrepancy between premature closure of external openings and fistulous tracts. Prolonged biological therapy until complete healing of anal fistulas confirmed on MRI might improve the results of treatment.


  • Palliative treatment of anal fistulas in Crohn's disease

    by Jacek Hermann, Piotr Eder, Tomasz Banasiewicz, Barbara Kołodziejczak, Liliana Łykowska‐Szuber

    Palliative and combined therapy for anal fistulas in Crohn's disease with surgery and infliximab or adalimumab therapy is an effective treatment for some patients.